Jianbing Wu

机构：Nanchang University, Nanjing University of Science and Technology, First Affiliated Hospital of Jiangxi Medical College, Zhongda Hospital Southeast University, Second Affiliated Hospital of Nanchang University, Lanzhou University · ORCID：0000-0002-4576-7286

发表论文 92 篇 · 总被引 3142 次 · h-index 21

代表论文

• Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study (2024 · EClinicalMedicine · 被引 154)
• Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 45)
• Damage behavior in Bi-2212 round wire with 3D elastoplastic peridynamic (2023 · Acta Mechanica Sinica · 被引 17)
• Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213) (2024 · Journal of Cachexia Sarcopenia and Muscle · 被引 15)
• USP11 promotes lipogenesis and tumorigenesis by regulating SREBF1 stability in hepatocellular carcinoma (2024 · Cell Communication and Signaling · 被引 14)
• Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆ (2024 · JHEP Reports · 被引 11)